Advanz Pharma, a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, agreed to acquire Europe, Canada and all other markets outside of the US businesses of Intercept Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, for $450m. “Acquiring this high-quality rare disease business outside of the US grows our position as a partner of choice for specialty and hospital pharmaceuticals in Europe, and we are thrilled to welcome Intercept’s dedicated and experienced team, which will bring additional capabilities to us for the benefit of patients. Today’s announcement furthers our purpose of improving the lives of patients by providing and enhancing the critical medicines they depend on,” Steffen Wagner, Advanz Pharma CEO.